MedTrace Logo

Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)

NCT01138267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-07-17

No results posted yet for this study

Summary

Objectives:

* To evaluate the impact of genetic polymorphism on ARV drug levels
* To evaluate the effect of genetic polymorphism/drug levels on long term immunologic and virologic response
* To correlate the genetic polymorphism/drug levels on antiretroviral toxicities

The long-term objective of this research plan is to characterize impact of pharmacogenomics to HIV drug concentration, toxicities, and response to antiretroviral therapy among HIV-infected adults. A comprehensive understanding of the impact of pharmacogenomics to HIV infection and HIV medication will lead to the development of appropriate intervention such as dose reduction strategies in patients with particular gene(s) correlated with higher drug levels. The dose reduction strategy will decrease long term drug toxicity and cost saving for Thais and Asian Ethnicities.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • Kirby Institute

    collaborator OTHER_GOV

  • Radboud University Medical Center

    collaborator OTHER

  • SEARCH Research Foundation

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Kiat Ruxrungtham, MD · Chulalongkorn University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01138267 on ClinicalTrials.gov